Retoxin

Retoxin (YY001) is a recombinant botulinum toxin type A developed by Chongqing Claruvis Pharmaceutical for the treatment of moderate to severe glabellar lines. It represents a significant technological advancement as the world's first botulinum toxin produced through a recombinant E. coli expression system, moving away from traditional natural extraction methods. The drug functions by targeting the neuromuscular junction, where it cleaves the synaptosomal-associated protein 25 (SNAP-25). This action prevents the release of the neurotransmitter acetylcholine, leading to a temporary reduction in muscle activity and the smoothing of facial wrinkles. In Phase III clinical trials (REFINE study), Retoxin demonstrated superior efficacy compared to onabotulinumtoxinA (Botox), achieving a significantly higher composite response rate at week 4. It has received official marketing approval from China's National Medical Products Administration (NMPA).

Brand names

Retoxin

Other names

recombinant botulinum toxin type Arecombinant botulinum neurotoxin type A for injection